We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01467882
First Posted: November 9, 2011
Last Update Posted: July 28, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Debiopharm International SA
November 7, 2011
November 9, 2011
June 25, 2015
September 4, 2015
July 28, 2017
April 2012
August 2013   (Final data collection date for primary outcome measure)
Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6 [ Time Frame: Month 6 ]
This is a lab test to see what percentage of participants were returned to normal before-puberty levels at Month 6.
Percentage of children with LH suppression to prepubertal levels 30 minutes after GnRH agonist stimulation at Month 6 (Day 169). [ Time Frame: Month 6 ]
Complete list of historical versions of study NCT01467882 on ClinicalTrials.gov Archive Site
  • Percentage of Children With LH Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Months 1, 2, 3, 9 and 12 [ Time Frame: at Months 1, 2, 3, 9 and 12 ]
    This is a lab test to see what percentage of children were returned to normal before-puberty levels by the drug at each time point.
  • Percentage of Children Maintaining LH Suppression at Prepubertal Levels 30 Minutes After Leuprolide Stimulation From Month 6 to 12 [ Time Frame: from Month 6 to 12 ]
    This is a lab test to see what percentage of children stayed at the normal before-puberty level from month 6 to month 12.
  • Percentage of Children With LH Suppression (LH ≤ 4 IU/L)30 Minutes After Leuprolide Stimulation at Months 1, 2, 3, 6, 9 and 12 [ Time Frame: at Months 1, 2, 3, 6, 9 and 12 ]
    This is a lab test to see what percentage of children were returned to lower than normal before-puberty levels by the drug at each time point.
  • Percentage of Children Maintaining LH Suppression at </= 4 IU/L 30 Minutes After Leuprolide Stimulation From Month 6 to 12 [ Time Frame: from Month 6 to 12 ]
    This is a lab test to see what percentage of children stayed at the lower than normal before-puberty level from month 6 to month 12.
  • Change From Baseline in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) at Months 1, 2, 3, 6, 9, and 12 [ Time Frame: Baseline to Months 1, 2, 3, 6, 9, and 12 ]
  • Change From Baseline in Estradiol Levels at Months 1, 2, 3, 6, 9, and 12 [ Time Frame: Baseline to Months 1, 2, 3, 6, 9, and 12 ]
  • Change From Baseline in Testosterone Levels at Months 1, 2, 3, 6, 9, and 12 [ Time Frame: Baseline to Months 1, 2, 3, 6, 9, and 12 ]
  • Percentage of Children With Prepubertal Estradiol or Testosterone Levels at Months 1, 2, 3, 6, 9, and 12 [ Time Frame: at Months 1, 2, 3, 6, 9, and 12 ]
  • Percentage of Children Without Higher Basal LH and Estradiol or Testosterone [ Time Frame: at 2 days after second triptorelin injection (Day 171) ]
  • Change From Baseline in Height-for-age Z-score Per 2000 CDC Growth Charts at Months 6 and 12 [ Time Frame: Baseline to Months 6 and 12 ]
  • Change From Baseline in Height-for-age Percentile Per 2000 CDC Growth Charts at Months 6 and 12 [ Time Frame: Baseline to Months 6 and 12 ]
  • Change From Baseline in Growth Velocity at Months 6 and 12 [ Time Frame: Baseline to Months 6 and 12 ]
  • Percentage of Participants Without Bone Age / Chronological Age Ratio Increase From Baseline at Months 6 and 12 [ Time Frame: Baseline to Months 6 and 12 ]
  • Percentage of Children Achieving Stabilization of Sexual Maturation at Months 6 and 12 [ Time Frame: at Months 6 and 12 ]
  • Percentage of Girls With Regression of Uterine Length Compared to Baseline at Months 6 and 12 [ Time Frame: Baseline to Months 6 and 12 ]
  • Percentage of Boys With Absence of Progression of Testis Volumes Compared to Baseline at Months 6 and 12 [ Time Frame: Baseline to Months 6 and 12 ]
Not Provided
Not Provided
Not Provided
 
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).
Not Provided
Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Central Precocious Puberty
Drug: Triptorelin
Powder and solution for solution for injection
Other Name: Trelstar
Experimental: Triptorelin
Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169
Intervention: Drug: Triptorelin

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
44
July 2014
August 2013   (Final data collection date for primary outcome measure)

Inclusion criteria:

  1. Onset of development of sex characteristics before 8 and 9 years in girls and boys, respectively (breast development in girls or testicular enlargement in boys according to the Tanner method), and candidate to receive at least 12 months of GnRH agonist therapy after study entry.
  2. Aged 2-8 years inclusive (i.e. < 9 years) for girls and 2-9 years inclusive (i.e. < 10 years) for boys at initiation of triptorelin treatment.
  3. Initiation of triptorelin treatment at the latest 18 months after onset of the first signs of precocious puberty.
  4. Difference (Δ) bone age (Greulich and Pyle method) - chronological age ≥ 1 year.
  5. Pubertal-type LH response 30 minutes following a GnRH agonist stimulation test before treatment initiation (leuprolide acetate 20 μg/kg SC) ≥ 6 IU/L.
  6. Clinical evidence of puberty, defined as Tanner Staging ≥ 2 for breast development for girls and testicular volume ≥ 4 mL (cc) for boys.
  7. Informed consent signed by one parent or both parents (as per local requirements), by the liable parent or by the legal guardian (when applicable); assent signed by the child if ≥ 7 years.

Non-inclusion criteria:

  1. Gonadotropin-independent (peripheral) precocious puberty: extra pituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroid secretion.
  2. Non-progressing isolated premature thelarche.
  3. Presence of an unstable intracranial tumour or an intracranial tumour requiring neurosurgery or cerebral irradiation. Patients with hamartomas not requiring surgery are eligible.
  4. Evidence of renal (creatinine > 2 x ULN) or hepatic impairment (bilirubin or ASAT > 3 x ULN).
  5. Any other condition or chronic illness or treatment possibly interfering with growth or other study endpoints (e.g. chronic steroid use [except mild topical steroids], renal failure, diabetes, moderate to severe scoliosis, previously treated intracranial tumour).
  6. Prior or current therapy with a GnRH agonist, medroxyprogesterone acetate, growth hormone or insulin-like growth factor-1 (IGF 1).
  7. Major medical or psychiatric illness that could interfere with study visits.
  8. Diagnosis of short stature, i.e. > 2.25 SD below the mean height for age.
  9. Positive pregnancy test.
  10. Known hypersensibility to any of the test materials or related compounds.
  11. Use of anticoagulants (heparin and coumarin derivatives).
Sexes Eligible for Study: All
2 Years to 9 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Chile,   Mexico,   United States
 
 
NCT01467882
Debio 8206-CPP-301
No
Not Provided
Not Provided
Debiopharm International SA
Debiopharm International SA
Not Provided
Principal Investigator: Tala Dajani, MD Pediatric Endocrinology of Phoenix, Arizona
Principal Investigator: Barry Reiner, MD Barry J. Reiner, MD, LLC, Baltimore, Maryland
Principal Investigator: Galal Salem, MD SRCR, Inc, Bell Gardens, California
Principal Investigator: Heidi Shea, MD Endocrine Associates of Dallas, Plano, Texas
Principal Investigator: Mark Rappaport, MD Pediatric Endocrine Associates, Atlanta, Georgia
Principal Investigator: Opada Alzohaili, MD Alzohaili Medical Consultants, Dearborn, Michigan
Principal Investigator: Quentin Van Meter, MD Van Meter Pediatric Endocrinology, Peachtree City, Georgia
Principal Investigator: David Domek, MD Lynn health Science Institute, Oklahoma City
Principal Investigator: Kathleen Bethin, MD Women's & Children's Hospital of Buffalo, New York
Principal Investigator: Paul Kaplowitz, MD Children's National Medical Center, Washington
Principal Investigator: Karen Klein, MD Children's National Medical Center, San Diego, California
Principal Investigator: Diane Merritt, MD Washington University, St. Louis, Missouri
Principal Investigator: Susan Rose, MD Cincinnati Children's Hospital, Ohio
Principal Investigator: Gad Kletter, MD Swedish Pediatric Specialist, Seattle, Washington
Principal Investigator: Javier Aisenberg, MD Hackensack university medical center, New Jersey
Principal Investigator: Dennis Brenner, MD St. Barnabas Medical Center, Livingston, New Jersey
Principal Investigator: Douglas Rogers, MD Cleveland Clinic, Ohio
Principal Investigator: Lawrence Silverman, MD Goryeb Children's Hospital, Morristown, New Jersey
Principal Investigator: Peter Lee, MD Penn State Hershey Children's Hospital, Pennsylvania
Principal Investigator: Ricardo Gomez, MD Children's Hospital, New Orleans, Louisiana
Principal Investigator: Fernando Cassorla, MD IDIMI, Santiago, Chile
Principal Investigator: Joshua Yang, MD Arnold Palmer Pediatric Endocrinology Practice, Orlando, Florida
Principal Investigator: Erica Eugster, MD James Whitcomb Riley Hospital for Children, Indianapolis, Indiana
Principal Investigator: Oscar Flores, MD Hospital Universitario de Monterrey, Mexico
Principal Investigator: Nancy Wright, MD Nancy Wright MD P.A., Tallahasse, Florida
Debiopharm International SA
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP